C12N 2760/18521
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2760/18521 (Viruses as such) appears on 32 US grants and 50 published applications in this corpus.
Search patents in C12N- Granted patents
- 32
- Published applications
- 50
- Assignees
- 39
- Inventors
- 101
- Latest grant
- 20 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 3 |
| 2003 | 0 | 0 |
| 2004 | 2 | 2 |
| 2005 | 1 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 2 | 3 |
| 2016 | 3 | 3 |
| 2017 | 1 | 3 |
| 2018 | 3 | 2 |
| 2019 | 2 | 6 |
| 2020 | 1 | 2 |
| 2021 | 5 | 4 |
| 2022 | 4 | 5 |
| 2023 | 0 | 5 |
| 2024 | 1 | 1 |
| 2025 | 3 | 3 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant RSV live vaccine strain and the preparing method thereof20 May 2025US 12,304,929 B2SK Bioscience Co., Ltd.
- Chimeric RSV, immunogenic compositions, and methods of use25 Mar 2025US 12,257,296 B2Emory University
- Methods and compositions for treating negative-sense single-stranded RNA virus18 Feb 2025US 12,227,769 B2Nationwide Children's Hospital, Inc.
- Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts5 Mar 2024US 11,918,638 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Attenuated virus strain and use thereof as a vaccine22 Nov 2022US 11,504,424 B2Centre National de la Recherche Scientifique (CNRS)
- Modified Viral Genome Compositions and Methods of Production and Use Thereof4 Jun 2026US 2026/0152727 A1The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges
- RSV Vaccines with Truncated G-Protein Mucin Domains30 Apr 2026US 2026/0115274 A1Butler University
- Methods and compositions for treating negative-sense single-stranded rna virus7 Aug 2025US 2025/0250548 A1Nationwide Children's Hospital, Inc.
- Recombinant live attenuated rsv vaccine strain and production method therefor24 Apr 2025US 2025/0127872 A1SK Bioscience Co., Ltd.
- Modified vero cells and methods of using the same for virus production10 Apr 2025US 2025/0115881 A1Sanofi Pasteur Limited
Most cited
By later US patents
- Respiratory virus nucleic acid vaccines53US 11,103,578 B2ModernaTX, Inc. · 2021
- Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins51US 6,790,449 B2The United States of America as represented by the Department of Health and Human Services · 2004
- Product of infectious respiratory syncytial virus from cloned nucleotide sequences37US 6,264,957 B1The United States of America as represented by the Department of Health and Human Services · 2001
- Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences24US 6,689,367 B1The United States of America as represented by the Department of Health and Human Services · 2004
- Human antibodies to respiratory syncytial virus F protein and methods of use thereof13US 9,447,173 B2Regeneron Pharmaceuticals, Inc. · 2016